Earnings Feed
Start Free
Home/Filings/3/0001209191-20-054238
3//SEC Filing

Versant Venture Capital VII, L.P. 3

Accession 0001209191-20-054238

CIK 0001435049other
View on SEC.govCompany Profile

Filed

Oct 6, 8:00 PM ET

Accepted

Oct 7, 8:25 PM ET

Size

11.0 KB

Accession

0001209191-20-054238

Insider Transaction Report

Form 3
Period: 2020-10-05
ADURO BIOTECH, INC.KDNY
Versant Voyageurs I Parallel, L.P.
10% Owner
Holdings

  • Common Stock

    (indirect: See footnote)
    4,733,023

  • Common Stock

    (indirect: See footnote)
    722,247

  • Common Stock

    (indirect: See footnote)
    2,433,099
Versant Venture Capital VII, L.P.
10% Owner
Holdings

  • Common Stock

    (indirect: See footnote)
    4,733,023

  • Common Stock

    (indirect: See footnote)
    2,433,099

  • Common Stock

    (indirect: See footnote)
    722,247
Versant Voyageurs I, L.P.
10% Owner
Holdings

  • Common Stock

    (indirect: See footnote)
    722,247

  • Common Stock

    (indirect: See footnote)
    4,733,023

  • Common Stock

    (indirect: See footnote)
    2,433,099
Footnotes (4)
  • [F1]The shares reported represent the number of shares of Issuer common stock received by the Reporting Person on the Effective Date in connection with the merger of Chinook Therapeutics U.S., Inc. ("Private Chinook") into the Issuer.
  • [F2]These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel Davis is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Jerel Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
  • [F3]These securities are held of record by Versant Voyageurs I Parallel L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel Davis is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Jerel Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
  • [F4]These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel Davis is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Jerel Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.

Documents

1 file

Issuer

ADURO BIOTECH, INC.

CIK 0001435049

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001750266

Filing Metadata

Form type
3
Filed
Oct 6, 8:00 PM ET
Accepted
Oct 7, 8:25 PM ET
Size
11.0 KB
View on SEC.gov